228 related articles for article (PubMed ID: 7531846)
21. Selective estrogen receptor modulators regulate stromal proliferation in human benign prostatic hyperplasia by multiple beneficial mechanisms--action of two new agents.
Kumar R; Verma V; Sarswat A; Maikhuri JP; Jain A; Jain RK; Sharma VL; Dalela D; Gupta G
Invest New Drugs; 2012 Apr; 30(2):582-93. PubMed ID: 21181231
[TBL] [Abstract][Full Text] [Related]
22. 5 alpha-reductase activity in cultured epithelial and stromal cells from normal and hyperplastic human prostates--effect of finasteride (Proscar), a 5 alpha-reductase inhibitor.
Boudon C; Lobaccaro JM; Lumbroso S; Lechevallier E; Mottet N; Gibelin B; Sultan C
Cell Mol Biol (Noisy-le-grand); 1995 Dec; 41(8):1007-15. PubMed ID: 8747081
[TBL] [Abstract][Full Text] [Related]
23. Inhibition of 5alpha-reductase in rat prostate reveals differential regulation of androgen-response gene expression by testosterone and dihydrotestosterone.
Dadras SS; Cai X; Abasolo I; Wang Z
Gene Expr; 2001; 9(4-5):183-94. PubMed ID: 11444528
[TBL] [Abstract][Full Text] [Related]
24. Prostate cancer cells differ in testosterone accumulation, dihydrotestosterone conversion, and androgen receptor signaling response to steroid 5α-reductase inhibitors.
Wu Y; Godoy A; Azzouni F; Wilton JH; Ip C; Mohler JL
Prostate; 2013 Sep; 73(13):1470-82. PubMed ID: 23813697
[TBL] [Abstract][Full Text] [Related]
25. Comparison of histological compositions and apoptosis in canine spontaneous benign prostatic hyperplasia treated with androgen suppressive agents chlormadinone acetate and finasteride.
Shibata Y; Fukabori Y; Ito K; Suzuki K; Yamanaka H
J Urol; 2001 Jan; 165(1):289-93. PubMed ID: 11125427
[TBL] [Abstract][Full Text] [Related]
26. Tissue effects of saw palmetto and finasteride: use of biopsy cores for in situ quantification of prostatic androgens.
Marks LS; Hess DL; Dorey FJ; Luz Macairan M; Cruz Santos PB; Tyler VE
Urology; 2001 May; 57(5):999-1005. PubMed ID: 11337315
[TBL] [Abstract][Full Text] [Related]
27. Role of canine basal cells in prostatic post natal development, induction of hyperplasia, sex hormone-stimulated growth; and the ductal origin of carcinoma.
Leav I; Schelling KH; Adams JY; Merk FB; Alroy J
Prostate; 2001 May; 47(3):149-63. PubMed ID: 11351344
[TBL] [Abstract][Full Text] [Related]
28. The effect of the steroidal androgen receptor antagonist, Win 49,596, on the prostate and testis of beagle dogs.
Juniewicz PE; McCarthy M; Lemp BM; Barbolt TA; Shaw C; Hollenbaugh DM; Winneker RC; Reel JR; Batzold FH
Endocrinology; 1990 May; 126(5):2625-34. PubMed ID: 1691701
[TBL] [Abstract][Full Text] [Related]
29. Dihydrotestosterone and the prostate: the scientific rationale for 5alpha-reductase inhibitors in the treatment of benign prostatic hyperplasia.
Andriole G; Bruchovsky N; Chung LW; Matsumoto AM; Rittmaster R; Roehrborn C; Russell D; Tindall D
J Urol; 2004 Oct; 172(4 Pt 1):1399-403. PubMed ID: 15371854
[TBL] [Abstract][Full Text] [Related]
30. Prevalent decrease of the EGF content in the periurethral zone of BPH tissue induced by treatment with finasteride or flutamide.
Monti S; Sciarra F; Adamo MV; Toscano V; Trotta MC; Martini C; Lanzara S; Silverio FD
J Androl; 1997; 18(5):488-94. PubMed ID: 9349746
[TBL] [Abstract][Full Text] [Related]
31. Effects of finasteride on size of the prostate gland and semen quality in dogs with benign prostatic hypertrophy.
Sirinarumitr K; Johnston SD; Kustritz MV; Johnston GR; Sarkar DK; Memon MA
J Am Vet Med Assoc; 2001 Apr; 218(8):1275-80. PubMed ID: 11330612
[TBL] [Abstract][Full Text] [Related]
32. Effect of combination treatment with zanoterone (WIN 49596), a steroidal androgen receptor antagonist, and finasteride (MK-906), a steroidal 5 alpha-reductase inhibitor, on the prostate and testes of beagle dogs.
Juniewicz PE; Hoekstra SJ; Lemp BM; Barbolt TA; Devin JA; Gauthier E; Frenette G; Dube JY; Tremblay RR
Endocrinology; 1993 Aug; 133(2):904-13. PubMed ID: 8393778
[TBL] [Abstract][Full Text] [Related]
33. The effect of dutasteride on intraprostatic dihydrotestosterone concentrations in men with benign prostatic hyperplasia.
Wurzel R; Ray P; Major-Walker K; Shannon J; Rittmaster R
Prostate Cancer Prostatic Dis; 2007; 10(2):149-54. PubMed ID: 17189955
[TBL] [Abstract][Full Text] [Related]
34. Cynanchum wilfordii Ameliorates Testosterone-Induced Benign Prostatic Hyperplasia by Regulating 5α-Reductase and Androgen Receptor Activities in a Rat Model.
Lee G; Shin J; Choi H; Jo A; Pan S; Bae D; Lee Y; Choi C
Nutrients; 2017 Sep; 9(10):. PubMed ID: 28953224
[TBL] [Abstract][Full Text] [Related]
35. Role of canine basal cells in postnatal prostatic development, induction of hyperplasia, and sex hormone-stimulated growth; and the ductal origin of carcinoma.
Leav I; Schelling KH; Adams JY; Merk FB; Alroy J
Prostate; 2001 Aug; 48(3):210-24. PubMed ID: 11494337
[TBL] [Abstract][Full Text] [Related]
36. 5 alpha-reductase inhibitors and prostatic disease.
Schröder FH
Clin Endocrinol (Oxf); 1994 Aug; 41(2):139-47. PubMed ID: 7522999
[TBL] [Abstract][Full Text] [Related]
37. A multiscale, mechanism-driven, dynamic model for the effects of 5α-reductase inhibition on prostate maintenance.
Zager MG; Barton HA
PLoS One; 2012; 7(9):e44359. PubMed ID: 22970204
[TBL] [Abstract][Full Text] [Related]
38. Morphological and hormonal changes in the ventral and dorsolateral prostatic lobes of rats treated with finasteride, a 5-alpha reductase inhibitor.
Prahalada S; Rhodes L; Grossman SJ; Heggan D; Keenan KP; Cukierski MA; Hoe CM; Berman C; van Zwieten MJ
Prostate; 1998 May; 35(3):157-64. PubMed ID: 9582084
[TBL] [Abstract][Full Text] [Related]
39. PNU 157706, a novel dual type I and II 5alpha-reductase inhibitor.
di Salle E; Giudici D; Radice A; Zaccheo T; Ornati G; Nesi M; Panzeri A; Délos S; Martin PM
J Steroid Biochem Mol Biol; 1998 Feb; 64(3-4):179-86. PubMed ID: 9605412
[TBL] [Abstract][Full Text] [Related]
40. 5alpha-reductase activity in the prostate.
Steers WD
Urology; 2001 Dec; 58(6 Suppl 1):17-24; discussion 24. PubMed ID: 11750244
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]